The anatomic and physiological differences between rabbit eyes and human eyes should be considered when applying the findings of this study to human eyes. Findings from this study suggest that release of drug from the DEX implant is relatively fast (1–2 months) in rabbit eyes compared with, for example, monkey eyes, in which DEX is released from the implant for up to 6 months.
24 The factors that can affect drug release from the implant are the implant characteristics (e.g., drug-polymer interactions), the solubility of drug in the vitreous humor, and the proximity of the implant to the primary elimination pathway.
33 –35 Given the lipophilic nature and the relatively low molecular weight of DEX, elimination is largely driven by diffusion through the retina.
36,37 In rabbit eyes, the implant is placed closer to the retina than in monkey eyes to avoid the large rabbit lens. Therefore, placement of the implant closer to the primary elimination pathway in rabbit eyes may increase the speed at which drug is released from the implant.
34 However, once drug is released, factors such as vitreoretinal kinetics and route of elimination govern the rate of drug clearance from the vitreous,
36 and the intravitreal half-life of DEX is expected to be similar between different species. Indeed, the estimated half-life of intravitreal DEX phosphate has been reported to be 3.5 hours in healthy rabbit eyes
29 and 5.5 hours in patient eyes coadministered DEX and vancomycin for the treatment of endophthalmitis.
38 Therefore, based on a vitreous volume of 1.4 mL in rabbit eyes and 4 mL in human eyes, we can estimate that the vitreal clearance of DEX is 8 mL/d in rabbit eyes and 12.1 mL/d in human eyes. These findings suggest that the vitreal clearance of the sustained-release DEX in human eyes is unlikely to be greatly different from the vitreal clearance observed in this study. Moreover, given that greater than 90% of DEX had been released from the DEX implant by day 31, this follow-up time was considered sufficient for determining the effect of vitrectomy on the pharmacokinetics of the DEX implant in rabbit eyes. Although this study was conducted for 1 month, pharmacokinetic data from a 9-month study of the DEX implant in primate eyes suggests that DEX is present at high concentrations in the vitreous humor and retina for up to 60 days and can be maintained for 6 months after administration of the implant.
24 These data support the clinical findings of the DEX implant in nonvitrectomized
13,25 –27 eyes of patients with persistent macular edema, in which the DEX implant was well tolerated and provided sustained improvements in visual acuity for 180 days.
13,25 –27 In addition, the sustained release of DEX in the present study was consistent with preliminary clinical evidence from an open-label study
39 of the DEX implant in vitrectomized eyes of patients with diabetic macular edema. In this pilot study, statistically significant improvements from baseline in central retinal thickness and visual acuity were observed 6 months after patients received the implant.